Therapeutic agent for lung cancer that has acquired egfr-tki resistance
AssigneeJapanese Foundation for Cancer Research
InventorsRyohei KATAYAMA, Ken UCHIBORI, Naoya FUJITA
Life of this patent
Estimating the term…
Abstract
A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
Claims18
A therapeutic agent for an EGFR gene mutations-positive non-small cell lung cancer, comprising, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable salt thereof:
- wherein R1 is a group represented by the following formula (II) or (III):
- R2 is —N(CH3)2, —NH2, or a group represented by the following formula (IV):
A method for testing efficacy of a drug by detecting a mutation at position 797 in EGFR in an EGFR gene mutations-positive non-small cell lung cancer, the drug comprising, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable salt thereof:
- wherein R1 is a group represented by the following formula (II) or (III):
- R2 is —N(CH3)2, —NH2, or a group represented by the following formula (IV):
A kit for testing efficacy of a drug, comprising PCR primers or an antibody for detecting a mutation at position 797 in EGFR, the drug comprising, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable salt thereof:
- wherein R1 is a group represented by the following formula (II) or (III)
- R2 is —N(CH3)2, —NH2, or a group represented by the following formula (IV)
Dependencies are inferred from the claim text.